464 related articles for article (PubMed ID: 17296529)
21. Choice of azathioprine or 6-mercaptopurine dose based on thiopurine methyltransferase (TPMT) activity to avoid myelosuppression. A prospective study.
Gisbert JP; Luna M; Maté J; González-Guijarro L; Cara C; Pajares JM
Hepatogastroenterology; 2006; 53(69):399-404. PubMed ID: 16795981
[TBL] [Abstract][Full Text] [Related]
22. Evolution of thiopurine use in pediatric inflammatory bowel disease in an academic center.
Banerjee S; Bishop WP
J Pediatr Gastroenterol Nutr; 2006 Sep; 43(3):324-30. PubMed ID: 16954954
[TBL] [Abstract][Full Text] [Related]
23. Immunosuppressive drugs in the treatment of inflammatory bowel disease.
Aranda R; Horgan K
Semin Gastrointest Dis; 1998 Jan; 9(1):2-9. PubMed ID: 9547850
[TBL] [Abstract][Full Text] [Related]
24. Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease.
Ansari A; Patel N; Sanderson J; O'Donohue J; Duley JA; Florin TH
Aliment Pharmacol Ther; 2010 Mar; 31(6):640-7. PubMed ID: 20015102
[TBL] [Abstract][Full Text] [Related]
25. Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease.
Hoentjen F; Seinen ML; Hanauer SB; de Boer NK; Rubin DT; Bouma G; Harrell LE; van Bodegraven AA
Inflamm Bowel Dis; 2013 Feb; 19(2):363-9. PubMed ID: 22605661
[TBL] [Abstract][Full Text] [Related]
26. Thiopurine metabolite monitoring in paediatric inflammatory bowel disease.
Ooi CY; Bohane TD; Lee D; Naidoo D; Day AS
Aliment Pharmacol Ther; 2007 Apr; 25(8):941-7. PubMed ID: 17402998
[TBL] [Abstract][Full Text] [Related]
27. Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease.
Wright S; Sanders DS; Lobo AJ; Lennard L
Gut; 2004 Aug; 53(8):1123-8. PubMed ID: 15247179
[TBL] [Abstract][Full Text] [Related]
28. The pharmacokinetic effect of discontinuation of mesalazine on mercaptopurine metabolite levels in inflammatory bowel disease patients.
Gilissen LP; Bierau J; Derijks LJ; Bos LP; Hooymans PM; van Gennip A; Stockbrügger RW; Engels LG
Aliment Pharmacol Ther; 2005 Oct; 22(7):605-11. PubMed ID: 16181300
[TBL] [Abstract][Full Text] [Related]
29. A nudge in the right direction: shaping the metabolic fate of thiopurines for therapeutic gain.
Egan LJ
Clin Gastroenterol Hepatol; 2007 Feb; 5(2):170-1. PubMed ID: 17296527
[No Abstract] [Full Text] [Related]
30. Split-dose administration of thiopurine drugs: a novel and effective strategy for managing preferential 6-MMP metabolism.
Shih DQ; Nguyen M; Zheng L; Ibanez P; Mei L; Kwan LY; Bradford K; Ting C; Targan SR; Vasiliauskas EA
Aliment Pharmacol Ther; 2012 Sep; 36(5):449-58. PubMed ID: 22784257
[TBL] [Abstract][Full Text] [Related]
31. The efficacy of low dose azathioprine/6-mercaptopurine in patients with inflammatory bowel disease.
Kim DU; Kim YH; Kim BJ; Chang DK; Son HJ; Rhee PL; Kim JJ; Rhee JC
Hepatogastroenterology; 2009; 56(94-95):1395-402. PubMed ID: 19950798
[TBL] [Abstract][Full Text] [Related]
32. Relationship between azathioprine dosage and thiopurine metabolites in pediatric IBD patients: identification of covariables using multilevel analysis.
Nguyen TV; Vu DH; Nguyen TM; Lachaux A; Boulieu R
Ther Drug Monit; 2013 Apr; 35(2):251-7. PubMed ID: 23503453
[TBL] [Abstract][Full Text] [Related]
33. Allopurinol enhances the activity of hypoxanthine-guanine phosphoribosyltransferase in inflammatory bowel disease patients during low-dose thiopurine therapy: preliminary data of an ongoing series.
Seinen ML; de Boer NK; Smid K; van Asseldonk DP; Bouma G; van Bodegraven AA; Peters GJ
Nucleosides Nucleotides Nucleic Acids; 2011 Dec; 30(12):1085-90. PubMed ID: 22132961
[TBL] [Abstract][Full Text] [Related]
34. Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease.
Jharap B; de Boer NK; Stokkers P; Hommes DW; Oldenburg B; Dijkstra G; van der Woude CJ; de Jong DJ; Mulder CJ; van Elburg RM; van Bodegraven AA;
Gut; 2014 Mar; 63(3):451-7. PubMed ID: 23424097
[TBL] [Abstract][Full Text] [Related]
35. Monitoring of azathioprine metabolites in pediatric patients with autoimmune hepatitis.
Nguyen TM; Daubard M; Le Gall C; Larger M; Lachaux A; Boulieu R
Ther Drug Monit; 2010 Aug; 32(4):433-7. PubMed ID: 20479703
[TBL] [Abstract][Full Text] [Related]
36. Allopurinol enhanced thiopurine treatment for inflammatory bowel disease: safety considerations and guidelines for use.
Min MX; Weinberg DI; McCabe RP
J Clin Pharm Ther; 2014 Apr; 39(2):107-11. PubMed ID: 24438369
[TBL] [Abstract][Full Text] [Related]
37. Optimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel disease.
Bradford K; Shih DQ
World J Gastroenterol; 2011 Oct; 17(37):4166-73. PubMed ID: 22072847
[TBL] [Abstract][Full Text] [Related]
38. Randomised clinical trial: efficacy, safety and dosage of adjunctive allopurinol in azathioprine/mercaptopurine nonresponders (AAA Study).
Friedman AB; Brown SJ; Bampton P; Barclay ML; Chung A; Macrae FA; McKenzie J; Reynolds J; Gibson PR; Hanauer SB; Sparrow MP
Aliment Pharmacol Ther; 2018 Apr; 47(8):1092-1102. PubMed ID: 29468701
[TBL] [Abstract][Full Text] [Related]
39. Long-term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease.
Ansari A; Elliott T; Baburajan B; Mayhead P; O'Donohue J; Chocair P; Sanderson J; Duley J
Aliment Pharmacol Ther; 2008 Sep; 28(6):734-41. PubMed ID: 19145729
[TBL] [Abstract][Full Text] [Related]
40. Optimising outcome on thiopurines in inflammatory bowel disease by co-prescription of allopurinol.
Smith MA; Blaker P; Marinaki AM; Anderson SH; Irving PM; Sanderson JD
J Crohns Colitis; 2012 Oct; 6(9):905-12. PubMed ID: 22386736
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
